Table S I.
Analysis of the evolution of the LP of the different generic Vinorelbine medicines approved in Spain with respect to the innovative drug.
| Drug type & company | CIPM approval date | Marketing authorization date | CIPM LP (€/mg)* | Interval since 1st Gx approval by CIPM (years) | Price difference vs innovative price | Price difference vs 1st Gx approved by CIPM |
|---|---|---|---|---|---|---|
| Innovative (Pierre Fabre) | 20/01/2001 | 01/07/1993 | 1.43 | NA | NA | NA |
| Generic 1 (Actavis) | 12/03/2009 | 04/11/2008 | 0.9 | 0 | -37% | NA |
| Generic 2 (IPS Pharma) | 29/11/2010 | 09/07/2010 | 0.69 | 1.7 | -52% | -23% |
| Generic 3 (Sandoz) | 30/06/2013 | 30/04/2009 | 0.63 | 4.3 | -56% | -30% |
| Generic 4 (Accord) | 28/02/2018 | 16/11/2007 | 0.63 | 9.0 | -56% | -30% |
* In the case of the innovative drug, the authorized LP at the time of marketing of the first generic drug is indicated.